Title |
Efficacy of lidocaine in patients receiving palliative care with opioid-refractory cancer pain with a neuropathic component: study protocol for a randomized controlled study
|
---|---|
Published in |
Trials, August 2014
|
DOI | 10.1186/1745-6215-15-318 |
Pubmed ID | |
Authors |
Sébastien Salas, Pascal Auquier, Florence Duffaud, Stéphanie Ranque Garnier, Mélanie Deschamps, Stéphane Honoré, Patrick Sudour, Karine Baumstarck |
Abstract |
The management of patients suffering from opioid-refractory cancer pain with a neuropathic component remains an important challenge for healthcare workers. Only one retrospective study specifically reported the use of intravenous (IV) lidocaine amongst the palliative care unit population, however, the study found that there was a positive response to this therapy. These preliminary uncontrolled results need to be confirmed by randomized controlled trials. The primary objective of this study is to assess the analgesic efficacy of IV lidocaine in patients in palliative care suffering from opioid-refractory cancer pain with a neuropathic component. The secondary objectives are to assess the tolerance of, symptomatology, and patient satisfaction with the therapeutic approach. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Switzerland | 1 | 25% |
Unknown | 3 | 75% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 4 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Italy | 1 | 1% |
Unknown | 88 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 11 | 12% |
Student > Master | 10 | 11% |
Student > Bachelor | 9 | 10% |
Student > Ph. D. Student | 8 | 9% |
Other | 8 | 9% |
Other | 13 | 15% |
Unknown | 30 | 34% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 25 | 28% |
Nursing and Health Professions | 11 | 12% |
Psychology | 4 | 4% |
Agricultural and Biological Sciences | 2 | 2% |
Biochemistry, Genetics and Molecular Biology | 2 | 2% |
Other | 10 | 11% |
Unknown | 35 | 39% |